Mufg Americas Holdings Corp Supernus Pharmaceuticals, Inc. Transaction History

Mufg Americas Holdings Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 30, 2021	SELL	$24.15 - $31.45 $3,525 - $4,591	-146 Closed	0 $0
Q4 2020 Dec 01, 2022	BUY	$17.7 - $25.81 $2,584 - $3,768	146 New	146 $4,000
Q4 2020 Feb 03, 2021	SELL	$17.7 - $25.81 $4,602 - $6,710	-260 Reduced 64.04%	146 $4,000
Q1 2018 May 07, 2018	SELL	$37.15 - $46.9 $4,643 - $5,862	-125 Reduced 23.54%	406 $19,000
Q4 2017 Feb 08, 2018	SELL	$36.4 - $42.6 $9,100 - $10,650	-250 Reduced 32.01%	531 $0
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $698 - $943	19 Added 2.49%	781 $0
Q2 2017 Aug 07, 2017	BUY	N/A	762	762 $0

279

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.01B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Mufg Americas Holdings Corp, based on Form 13F filings with the SEC.

Stay updated on Mufg Americas Holdings Corp with notifications on news.